Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03473600|
Recruitment Status : Not yet recruiting
First Posted : March 22, 2018
Last Update Posted : March 22, 2018
Alopecia areata is the most frequent cause of inflammation-induced hair loss with prevalence from 0.1 to 0.2%. It has no age nor sex predilection .
Clinically, alopecia areata presents as a well-circumscribed patch of sudden hair loss. It affects any hair bearing area. The most common affected site is the scalp. Based on site and extent, AA can be classified into; diffuse, multi-locularis, mono-locularis, totalis, universalis, and ophiasis.
|Condition or disease||Intervention/treatment||Phase|
|Alopecia Areata||Procedure: Cryotherapy Drug: Triamcinolone acetonide injection||Phase 4|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation|
|Estimated Study Start Date :||November 2018|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||September 2019|
Experimental: study group
•The first group (20 patients) will be treated with cryotherapy using liquid nitrogen spray, two cycles each one 3-5 seconds, one session every two weeks, for three months.
Liquid Nitrogen spray
Active Comparator: control group
•The second group (20 patients) will be treated with intralesional injection of 4mg/ml/ session of triamcinolone-acetonide, it will be injected into deep dermis or upper subcutaneous tissue using a 0.5-inch long 30-gauge needle at multiple sites, 1 cm apart and 0.1 ml into each site, once every three weeks, for three months, using insulin syringes.
Drug: Triamcinolone acetonide injection
Intralesional Triamcinolone Acetonide injection
- The incidence of patietns with hair regrowth [ Time Frame: 3 months ]measuring severity of alopecia tool score and dermoscopic examination
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03473600
|Contact: Hanan Ahmed Morsy, Assistant professor||01064447881||Hanan_morsy2003@yahoo.com|
|Contact: Aya Youssef Mohamed, Lecturer||01013244819||Aya_badran@yahoo.com|
|Faculty of medicine||Not yet recruiting|
|Assiut, Egypt, 71111|
|Contact: Aya Youssef, Lecturer 01013244819|